Scholar Rock Holding Corp

Scholar Rock has removed Catalent Indiana from all commercial fill-finish roles for apitegromab, with the FDA continuing to review its U.S. BLA using an alternate, previously inspected facility and the company preparing for launch upon a potential decision by the September 30, 2026 PDUFA date. The company also reset its global regulatory plan by withdrawing and planning to resubmit its European filing with the new facility, while securing PMDA agreement to file a Japanese NDA for apitegromab without local clinical trials, an unusual path that could simplify entry into one of the world's larger rare disease markets. Scholar Rock's narrative projects $402.0 million revenue and $76.0 million earnings by 2029, implying an earnings increase of about $484.7 million from -$408.7 million today. Three Simply Wall St community valuations span roughly US$59 to US$191 per share, showing how far apart individual expectations can sit.

Scholar Rock Holding Corporation is removing the Catalent Indiana fill-finish facility, now part of Novo Nordisk, from its apitegromab Biologics License Application after the FDA classified an April 2026 site inspection as Official Action Indicated. The company pivoted exclusively to its second fill-finish facility, submitted the data package ahead of schedule, and confirmed robust commercial supply, keeping the apitegromab BLA on track for its September 30, 2026 PDUFA date. Scholar Rock reported a narrower-than-expected Q2 2026 net loss of $0.84 per share, or $109.9 million, and exited the quarter with $492 million in cash. BMO Capital raised its price target to $76 from $70, citing confidence ahead of the apitegromab decision. Novo Nordisk, the parent of the Catalent site, reported an 11% increase in adjusted operating profit to DKK 33.38 billion, but its reported operating profit dropped 16% to DKK 27.06 billion due to non-cash impairment charges of DKK 6.3 billion and unfavorable comparisons to prior-year US 340B rebate provision reversals, leading Citi to lower its price target to DKK 310 from DKK 330 and call the quarter messy.

Scholar Rock announced that the FDA review of its apitegromab Biologics License Application for spinal muscular atrophy will progress solely with the company's second fill-finish facility, after Catalent Indiana received an Official Action Indicated classification from the FDA. The company received notification on August 7, 2026, that the FDA classified the April 2026 site inspection of Catalent Indiana as OAI, and under FDA guidance, Scholar Rock will remove that facility from the BLA. The data package for the second fill-finish facility, agreed upon at a March 2026 Type C meeting, has been submitted ahead of schedule, and robust commercial supply is ready for launch upon potential approval by the September 30, 2026 PDUFA action date. Scholar Rock is also engaging with the European Medicines Agency on including the second facility in its Marketing Authorisation Application.

Several biotech stocks reached 52-week highs on July 10, 2026, driven by regulatory updates and quarterly results. American Well Corporation hit $10.16, closing at $9.91, after a Nature report validated its SilverCloud platform and it facilitated a DarioHealth insurer agreement, though full-year 2026 revenue is expected at $195 million to $205 million, below 2025's $249.3 million. Cue Biopharma reached $45.50 and announced a roughly $50 million private placement, while advancing CUE-221 in a Phase 2 allergy study and planning an IND for CUE-401. ImmuCell climbed to $11.59 after reporting unaudited second-quarter sales of $7.2 million, an 11.5% year-over-year increase, with $4.9 million from Tri-Shield First Defense. Scholar Rock hit $58.49, up 3.33%, as its BLA for Apitegromab in SMA is under FDA review with a decision expected by September 30, 2026. Faeth Therapeutics touched $36.89, advancing the PIKTOR combination therapy in a Phase 1/2 breast cancer trial with interim data due in 2027 and a Phase 2 endometrial cancer trial with topline data expected in the second half of 2026.

Scholar Rock announced it will present new clinical data and research updates at two upcoming neuromuscular disease conferences. The presentations will feature analyses from the Phase 3 SAPPHIRE trial and the Phase 2 FORGE study of its investigational drug apitegromab. At the Cure SMA Annual Research and Clinical Care Meeting in Orlando, the company will share post hoc analyses of apitegromab in nonambulatory type 2 or 3 spinal muscular atrophy, an assessment of motor scale impacts on patient independence, and an evaluation of baseline characteristics on efficacy. At the FSHD Society's International Research Congress in Chicago, Scholar Rock will present the trial design for the Phase 2 FORGE study evaluating apitegromab in adults with facioscapulohumeral muscular dystrophy.